Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases

Toxicol In Vitro. 2023 Aug 17:105664. doi: 10.1016/j.tiv.2023.105664. Online ahead of print.ABSTRACTPonatinib is an efficient oral tyrosine kinase inhibitor (TKI) for T315I-positive Ph + ALL and T315I-positive chronic myeloid leukemia (CML) or BCR-ABL when no other TKIs can be prescribed. In this research, we evaluated the inhibitory effects of ponatinib on human recombinant UDP-glucuronosyltransferases (UGTs) and predicted the magnitude of potential drug-drug interaction (DDI) risk of co-treatment with ponatinib and UGTs substrates by using in vitro-in vivo extrapolation (IVIVE) method. Our study presented that ponatinib showed a broad-spectrum inhibition against UGTs. Particularly, ponatinib exhibited potent inhibitory effects towards UGT1A7, UGT1A1, and UGT1A9 with IC50 values of 0.37, 0.41, and 0.89 μM, respectively, which might lead to clinically significant DDI.PMID:37597759 | DOI:10.1016/j.tiv.2023.105664
Source: Toxicology in Vitro - Category: Toxicology Authors: Source Type: research